qpi-1007
Nucleic acidexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT01064505)
Timeline
Indications
Mechanism of action
- Caspase-2INHIBITOR
CASP2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- qpi-1007
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02341560 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2015 | Quark Pharmaceuticals |
| NCT01965106 | Phase 2 | Dec 1, 2013 | Quark Pharmaceuticals |
| NCT01064505 | Phase 1 | Feb 1, 2010 | Quark Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Quark Pharmaceuticals | For profit | 3 | 3 | 3 | 2010 |
1 organizations
Page 1 / 1